Abstract: Use of soluble CD14 (sCD14) for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a chronic inflammation condition and a clinical disorder associated with insulin resistance in an animal or a human. Examples of diseases include type 2 diabetes mellitus, obesity, metabolic syndrome, arteriosclerotic disease, arterial hypertension and functional ovaric hyperandrogenism.
Abstract: Use of a bactericidal/permeability-increasing (BPI) protein product for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a clinical disorder associated with insulin resistance in a human.
Type:
Application
Filed:
July 7, 2006
Publication date:
August 27, 2009
Applicant:
BRIDGE BIORESEARCH LIMITED
Inventors:
Jose Manuel Fernandez-Real Lemos, Wifredo Ricart Engel
Abstract: Stable salts of S-adenosil-L-methionine (SAM) with sulphonic acids chosen from the group consisting of methanesulphonic, ethanesulphonic, 1-n-dodecanesulphonic, 1-n-octadecanesulphonic, 2-chloroethanesulphonic, 2-bromoethanesulphonic, 2-hydroxyethanesulphonic, 3-hydroxypropanesulphonic, d-, 1, -d, 1-10-camphorsulphonic, d-, 1-, d, 1-3-bromocamphor-10-sulphonic, cysteic, benzenesulphonic, p-chlorobenzenesulphonic, 2-mesitylbenzenesulphonic, 4-biphenylsulphonic, 1-naphthalenesulphonic, 2-naphthalenesulphonic, 5-sulphosalicylic, p-acetylbenzenesulphonic, 1,2-ethanedisulphonic, o-benzenedisulphonic and chondroitinesulphuric acids, and double salts of said acids with sulphuric acid.
Abstract: Double salts of S-adenosyl-L-methionine are prepared by the action of the enzyme ATP-methionine-adenosyltransferase on a mixture of adenosine triphosphate and methionine and subsequently precipitating said double salts with picrolonic acid, p-toluenesulphonic acid, sulphuric acid and organic solvents.
Abstract: New double salts extremely stable of S-Adenosil-L-methionine with sulphuric acid and p.toluensulphonic acid of the formula SAM.sup.+.HSO.sub.4 .sup.-.H.sub.2 SO.sub.4.2CH.sub.3 C.sub.6 H.sub.4 SO.sub.3 H and SAM.sup.+.HSO.sub.4 .sup.-.H.sub.2 SO.sub.4.CH.sub.3 C.sub.6 H.sub.4 SO.sub.3 H, process for the preparation thereof and therapeutic compositions containing them.